| 000 | 00870 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517180135.0 | ||
| 264 | 0 | _c20180430 | |
| 008 | 201804s 0 0 eng d | ||
| 022 | _a2352-3018 | ||
| 024 | 7 |
_a10.1016/S2352-3018(17)30180-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBoyd, Mark A | |
| 245 | 0 | 0 |
_aTowards a universal second-line fixed-dose combination ART. _h[electronic resource] |
| 260 |
_bThe lancet. HIV _c01 2018 |
||
| 300 |
_ae3-e5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAnti-HIV Agents |
| 650 | 0 | 4 | _aHIV Infections |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aNevirapine |
| 700 | 1 | _aCooper, David A | |
| 700 | 1 | _aGilks, Charles F | |
| 773 | 0 |
_tThe lancet. HIV _gvol. 5 _gno. 1 _gp. e3-e5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S2352-3018(17)30180-7 _zAvailable from publisher's website |
| 999 |
_c27646360 _d27646360 |
||